Effectiveness of the CardioPain initiative in reducing inappropriate NSAID prescriptions in pain therapy among high cardiovascular risk patients: an informative Italian survey
Aims. Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors (COXIBs) may be associated with increased cardiovascular (CV) risk and mortality in CV patients. After the release of Note 66 by Agenzia Italiana del Farmaco (AIFA) to reduce inappropriate prescribing of NSAIDs and COXIBs, the CARDIOPAIN initiative was started in Italy to include such recommendations into the hospital discharge letter of patients with high CV risk. We evaluated the effect of the CARDIOPAIN initiative on the prescription of analgesic drugs by general practitioners (GPs). Methods. An online interview was proposed to 414 Italian GPs. A descriptive statistic was reported. Results. Three groups of GPs were identified: those who found the Note 66 recommendations in most hospital discharge letters (the “MOST” group), those who found them in only few cases (the “FEW” group) and those who never found the recommendations (the “NO” group). In patients with high CV risk, the percentage of GPs prescribing NSAIDs as first choice in pain management was lower in the MOST group compared with the “FEW” or “NO” groups. GPs belonging to the “MOST” group prescribed NSAIDs in 28% of cases, compared with 50% of cases observed for GPs belonging to the “NO” group. The more severe the pathology the fewer the NSAID prescriptions, in favor of opioid agents administration. Conclusions. Our results suggest that the inclusion of the AIFA Note 66 in the discharge documents of high CV risk patients may have contributed to lower inappropriate NSAID prescriptions in Italian GPs. Presumably, a wider diffusion of the CARDIOPAIN initiative might improve the prescription appropriateness of analgesic drugs.
Inappropriate prescription, NSAIDs, Cardiovascular risk, Questionnaire
Financial support: This research was made possible by an unrestricted
educational grant from Mundipharma Pharmaceuticals Srl.
Valentina Orlando CIRFF, Center of Pharmacoeconomics Federico II University of Naples D. Montesano 49 80131 Naples, Italy email@example.com
Editorial assistance was provided by HPS—Health Publishing and
Services Srl (Milan, Italy).
Share this Article
Related Content In Atherosclerosis
Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden
Heart International. 2022;16(1):2–11 DOI: https://doi.org/10.17925/HI.2022.16.1.2
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]
The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
Heart International. 2021;15(1):7-13 DOI: https://doi.org/10.17925/HI.2021.15.1.7
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce the residual risk of cardiovascular disease (CVD) events.1 There is increased focus on the role […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!